The estimated Net Worth of Oxana Beskrovnaya is at least 6.85 百万$ dollars as of 11 September 2024. Dr Beskrovnaya owns over 2,161 units of Dyne Therapeutics stock worth over 4,652,476$ and over the last 4 years he sold DYN stock worth over 2,194,441$.
Dr has made over 16 trades of the Dyne Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,161 units of DYN stock worth 68,914$ on 11 September 2024.
The largest trade he's ever made was selling 87,779 units of Dyne Therapeutics stock on 3 January 2024 worth over 1,630,056$. On average, Dr trades about 5,933 units every 45 days since 2020. As of 11 September 2024 he still owns at least 142,714 units of Dyne Therapeutics stock.
You can see the complete history of Dr Beskrovnaya stock trades at the bottom of the page.
Dr. Oxana Beskrovnaya Ph.D. is the Chief Scientific Officer at Dyne Therapeutics.
Dr D is 60, he's been the Chief Scientific Officer of Dyne Therapeutics since . There are 1 older and 24 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.
Oxana's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over 197,573,300$ worth of Dyne Therapeutics stock and bought 5,790,447 units worth 92,382,301$ . The most active insiders traders include Capital Management, L.P.Kol...、Jason P Rhodes、Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of 3,566,016$. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth 68,914$.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: